Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KB-9558
- Development stage
- Preclinical
- Lead developer
- Concentra Biosciences
- Modality
- Small Molecules
01
Overview
KB-9558 is a preclinical small molecule drug developed by Kronos Bio that targets the lysine acetyltransferase (KAT) domain of p300, a critical cofactor in the IRF4 transcription regulatory network. By inhibiting p300’s KAT activity, KB-9558 downregulates IRF4 expression—a key driver of multiple myeloma cell survival and proliferation. Preclinical studies have shown that treatment with KB-9558 leads to rapid and potent suppression of IRF4, resulting in anti-tumor effects in multiple myeloma models. The drug is also being explored for HPV-driven tumors due to its ability to disrupt viral oncogene expression via p300 inhibition[1][2][3][5][6][7].
02
Targets
IRF4 (Interferon regulatory factor 4)EP300 (Histone acetyltransferase p300)
Beyond the preview
Go deeper on KB-9558.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KB-9558.